Inflammatory Bowel Diseases

Immunology
7
Pipeline Programs
10
Companies
12
Clinical Trials
1 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
1
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
375%
Vaccine
125%
+ 9 programs with unclassified modality

On Market (2)

Approved therapies currently available

U
REMICADEApproved
infliximab
Unknown Company
Tumor Necrosis Factor Blocker [EPC]intravenous1998
M&
ZINPLAVAApproved
bezlotoxumab
Merck & Co.
injection2016

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Celltrion
CelltrionKorea - Incheon
3 programs
1
1
InfliximabPhase 4Monoclonal Antibody1 trial
CT-P13Phase 31 trial
Subcutaneous infliximab CT-P13 Remsima®SCN/A1 trial
Active Trials
NCT04990258UnknownEst. Sep 2024
NCT06274294UnknownEst. Jan 2025
NCT06113913RecruitingEst. Nov 2026
M&
Merck & Co.RAHWAY, NJ
1 program
1
BezlotoxumabPhase 4Monoclonal Antibody1 trial
Active Trials
NCT04626947Terminated19Est. May 2024
H
HutchmedChina - Hong Kong
1 program
1
HMPL-011 tabletsPhase 11 trial
Active Trials
NCT03860532Completed24Est. Dec 2011
CT
1 program
1
TQH3906 capsulesPhase 11 trial
Active Trials
NCT06754891Not Yet RecruitingEst. Dec 2027
Takeda
TakedaTOKYO, Japan
2 programs
Remote monitoring toolN/A1 trial
Subcutaneous vedolizumabN/AMonoclonal Antibody1 trial
Active Trials
NCT04151420Completed584Est. Feb 2022
NCT05158517Active Not Recruiting349Est. Mar 2025
Alliance Pharmaceuticals
1 program
COVID-19 VaccineN/AVaccine
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
Health CoachingN/A1 trial
Active Trials
NCT03757533Completed43Est. Jul 2023
Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
1 program
Individualization Treatment Through a Self-managed Web-based Solution in Ulcerative ColitisN/A1 trial
Active Trials
NCT03604536Terminated1Est. Dec 2021
Providence Therapeutics
1 program
Intervention GroupN/A1 trial
Active Trials
NCT04067778CompletedEst. Oct 2022
Alder Therapeutics
Alder TherapeuticsSweden - Solna
1 program
Intervention groupN/A1 trial
Active Trials
NCT03170622Completed210Est. Jun 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
CelltrionInfliximab
Merck & Co.Bezlotoxumab
CelltrionCT-P13
Chia Tai TianQing Pharmaceutical GroupTQH3906 capsules
HutchmedHMPL-011 tablets
TakedaSubcutaneous vedolizumab
CelltrionSubcutaneous infliximab CT-P13 Remsima®SC
Providence TherapeuticsIntervention Group
TakedaRemote monitoring tool
Ferring PharmaceuticalsIndividualization Treatment Through a Self-managed Web-based Solution in Ulcerative Colitis
AbbVieHealth Coaching
Alder TherapeuticsIntervention group

Clinical Trials (12)

Total enrollment: 1,230 patients across 12 trials

NCT06113913CelltrionInfliximab

Subcutaneous Infliximab After A Previous Intravenous Dose Optimization

Start: Apr 2024Est. completion: Nov 2026
Phase 4Recruiting
NCT04626947Merck & Co.Bezlotoxumab

Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).

Start: Oct 2021Est. completion: May 202419 patients
Phase 4Terminated
NCT06274294CelltrionCT-P13

Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous as Induction Therapy in Patients With Active CD or UC

Start: Jul 2024Est. completion: Jan 2025
Phase 3Unknown
NCT06754891Chia Tai TianQing Pharmaceutical GroupTQH3906 capsules

Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Start: Jan 2025Est. completion: Dec 2027
Phase 1Not Yet Recruiting
NCT03860532HutchmedHMPL-011 tablets

Phase I Clinical Trial in Healthy Male Volunteers

Start: Sep 2011Est. completion: Dec 201124 patients
Phase 1Completed
NCT05158517TakedaSubcutaneous vedolizumab

VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Subcutaneous Administration : a Real-life Multicenter Study (DOPER)

Start: Mar 2022Est. completion: Mar 2025349 patients
N/AActive Not Recruiting
NCT04990258CelltrionSubcutaneous infliximab CT-P13 Remsima®SC

A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC

Start: Sep 2021Est. completion: Sep 2024
N/AUnknown
NCT04067778Providence TherapeuticsIntervention Group

IBD Neoplasia Surveillance Pilot RCT

Start: Nov 2020Est. completion: Oct 2022
N/ACompleted
NCT04151420TakedaRemote monitoring tool

Real Life Remote Monitoring of Mild, Moderate and Severe Infectious Complications in IBD by Patient Reported Assessment

Start: Jun 2020Est. completion: Feb 2022584 patients
N/ACompleted
NCT03604536Ferring PharmaceuticalsIndividualization Treatment Through a Self-managed Web-based Solution in Ulcerative Colitis

Individualization Treatment Through a Self-managed Web-based Solution in Ulcerative Colitis

Start: Dec 2019Est. completion: Dec 20211 patients
N/ATerminated
NCT03757533AbbVieHealth Coaching

Health Coaching as a Tool for Improving Medication Adherence in Adult Patients With Inflammatory Bowel Disease

Start: Jun 2019Est. completion: Jul 202343 patients
N/ACompleted
NCT03170622Alder TherapeuticsIntervention group

Evaluation of Faecal Volatile Organic Compounds in the Diagnosis of Paediatric Inflammatory Bowel Disease

Start: Oct 2017Est. completion: Jun 2019210 patients
N/ACompleted

Related Jobs in Immunology

Regulatory Affairs Manager(Immunology), Korea

AbbVie
Seoul, Seoul
6h ago

Regional Sales Trainer - Rheumatology (Mid Atlantic/Central)

AbbVie
Remote
7h ago

Product Specialist - Immunology

Johnson & Johnson
Kibbutz Shefayim, Center District, Israel
20h ago

Senior Area Business Specialist, Immunology - Detroit, MI - Johnson & Johnson Innovative Medicine

Johnson & Johnson
Detroit, Michigan, United States
20h ago

Senior Medical Science Liaison, Dermatology - Indianapolis

Johnson & Johnson
Indianapolis, Indiana, United States
20h ago
$137K - $236K/yr

Field Reimbursement Manager - Rheumatology - Seattle, WA (North)

Johnson & Johnson
Seattle, Washington, United States of America
20h ago
$100K - $175K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,230 patients
10 companies competing in this space

Related Indications

Rheumatoid Arthritis(475)Psoriasis(206)Ulcerative Colitis(151)Atopic Dermatitis(144)Crohn's Disease(140)Systemic Lupus Erythematosus(85)Arthritis, Rheumatoid(61)Plaque Psoriasis(53)Crohn Disease(49)Ankylosing Spondylitis(33)